Filter

31-40 of 107 results

  • Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020

    Issue Brief

    Recent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices for Medicare and private insurance exceed the rate of inflation. As context for understanding the possible impact of this proposal, this analysis compares price changes for drugs covered by Medicare Part B (administered by physicians) and Part D (retail prescription drugs) between 2019 and 2020 to the inflation rate over the same period.

  • Webinar: How Might the Pandemic Affect Health Premiums, Utilization, and Outcomes in 2021 and Beyond?

    Event Date:
    Event

    As the coronavirus pandemic enters its eighth month, we are still facing uncertainty about what the long-term impact of the crisis will be for the health sector, and for patients. However, the extent to which costs grow, and how the burden is distributed across payers, programs, individuals, outcomes, and geography are still very much unknown. On Monday, October 19, KFF held a webinar on the outlook for the U.S. health system in light of the…

  • Unpacking the Prescription Drug Provisions of the Build Back Better Act

    Event Date:
    Event

    As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs. The House-passed bill would allow the federal government to negotiate prices for some high-cost drugs in Medicare, and set a hard cap on out-of-pocket drug spending for Medicare Part D enrollees.  For people with Medicare and private insurance, the legislation would limit annual increases in drug prices and cap…

  • A Preview of the Role Health Care May Play in the 2026 Election

    Issue Brief

    Ahead of the 2026 midterm elections, this KFF issue brief examines the role health care has played in previous elections and what that may suggest about its potential role in 2026. KFF polls have consistently found that the cost of health care is an important part of voters’ economic concerns.

  • BTD Health Policy in 2026

    Health Policy in 2026

    From Drew Altman

    In a new column, President and CEO Dr. Drew Altman forecasts eight things to look for in health policy in 2026. “First and foremost,” he writes, “is the role health care affordability will play in the midterms.” And, he notes: “The average cost of a family policy for employers could approach $30,000 and cost sharing and deductibles will rise again after plateauing for several years.”

  • Why Affordability Is the Big Tent

    From Drew Altman

    In this column, KFF President and CEO Drew Altman explores why the public's concerns about out-of-pocket health costs make health care affordability the health policy issue most likely to resonate with voters across the political spectrum.

  • How Medicare Negotiated Drug Prices Compare to Other Countries

    Issue Brief

    This analysis finds that Medicare's negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is available on the Peterson-KFF Health System Tracker.